Sudden cardiac death accounts for approximately 50%
|
|
- Clifton Neal
- 5 years ago
- Views:
Transcription
1 Annals of Internal Medicine Article Implantable Cardioverter Defibrillators in Primary and Secondary Prevention: A Systematic Review of Randomized, Controlled Trials Justin A. Ezekowitz, MB, BCh; Paul W. Armstrong, MD, FRCPC; and Finlay A. McAlister, MD, MSc, FRCPC Background: Sudden cardiac death is common in persons with cardiovascular disease. Purpose: To assess the efficacy of implantable cardioverter defibrillators (ICDs) in persons at increased risk for sudden cardiac death. Data Sources: MEDLINE ( ), EMBASE ( ), Cochrane Controlled Clinical Trial Registry (2002, Volume 3), other databases, and conference proceedings. Primary study authors and device manufacturers were contacted, and bibliographies of relevant papers were hand searched. Study Selection: Randomized, controlled clinical trials evaluating ICDs versus usual care were selected. Data Extraction: Two reviewers extracted data independently. Data Synthesis: Eight trials were included in the final analysis (4909 patients, 1154 deaths). Compared with usual care (most commonly amiodarone therapy), ICDs significantly reduced sudden cardiac death (relative risk [RR], 0.43 [95% CI, 0.35 to 0.53]) and all-cause mortality (RR, 0.74 [CI, 0.67 to 0.82]). The included trials were divided a priori into two categories: secondary prevention (involving patients resuscitated after cardiac arrest or unstable ventricular tachycardia or ventricular fibrillation [n 1963]) and primary prevention (involving patients at increased risk for sudden cardiac death but without documented cardiac arrest, ventricular fibrillation, or ventricular tachycardia [n 2946]). Regardless of baseline risk, ICDs were equally efficacious in preventing sudden cardiac death in both types of trials (RR, 0.50 [CI, 0.38 to 0.66] for secondary prevention vs [CI, 0.27 to 0.50] for primary prevention). However, the magnitude of benefit in total mortality varied within the primary prevention trials depending on baseline risk for sudden cardiac death. Conclusions: Implantable cardioverter defibrillators prevent sudden cardiac death regardless of baseline risk. However, their impact on total mortality is sensitive to baseline risk for arrhythmic death. Decisions about resource allocation for ICDs depend on accurate stratification of patients according to risk. Ann Intern Med. 2003;138: For author affiliations, see end of text. See editorial comment on pp Sudden cardiac death accounts for approximately 50% of all deaths from cardiovascular causes (1, 2). Some patients are at higher risk for sudden cardiac death, particularly those with significant coronary artery disease (CAD) and left ventricular systolic dysfunction. Until recently, prevention of sudden cardiac death has focused on antiarrhythmic drugs, -blockers, and improved management of the underlying disease processes. Several published trials in the past few years have evaluated implantable cardioverter defibrillators (ICDs) in patients with cardiovascular disease. There seems to be little doubt that this intervention should be routinely considered in some patients, such as those with advanced ischemic cardiomyopathy who are resuscitated after ventricular fibrillation arrest. However, debate continues about the potential benefits of ICDs in other patient groups (3 6). Approximately 85% to 90% of sudden cardiac deaths are due to a first arrhythmic event; the remaining 10% to 15% are due to recurrent events (7). We defined primary prevention as prevention of a first life-threatening arrhythmic event (ventricular fibrillation, sustained ventricular tachycardia, or cardiac arrest) (8). Primary prevention of sudden cardiac death routinely focuses on patients at high risk, including those with CAD and left ventricular systolic dysfunction, up to 60% of whom die of dysrhythmia (9). Secondary prevention refers to the prevention of an additional life-threatening arrhythmic event in survivors of sudden cardiac death or patients with recurrent unstable rhythms. A recent meta-analysis using individual-patient data from three studies of secondary prevention suggested a survival benefit for ICD therapy compared with amiodarone therapy but did not include any data on primary prevention (10). Another recent systematic review involving 1610 patients included trials of primary and secondary prevention published before January 2000 (11); however, two primary prevention trials involving 1336 patients have been published since then (12, 13). These trials, in turn, focused exclusively on total mortality and did not calculate summary effect estimates or explore reasons for heterogeneity in the total mortality data. Given the limitations of the existing analyses, the potential impact of ICDs on patient survival, and the major socioeconomic implications of this issue, we performed a systematic review of trials of primary and secondary prevention with ICDs to examine the effects of this therapy on rates of sudden cardiac death and all-cause mortality. METHODS Search Strategy We searched for randomized trials in MEDLINE ( September 2002), the Cochrane Controlled Clinical Trial Registry (2002, Volume 3), EMBASE ( ), Web of Science, National Library of Medicine Gateway, Cardiosource, the Clinical Trials Registry, Clinicaltrials.gov, the CRISP (Computer Retrieval of Information on Scientific Projects) Database, the National 2003 American College of Physicians American Society of Internal Medicine 445
2 Article Defibrillators and Sudden Cardiac Death Context Implantable cardioverter defibrillators (ICDs) clearly prevent death from cardiac arrhythmias, but in which patients? Contribution This meta-analysis summarizes findings from eight randomized trials that compared ICDs with usual care or antiarrhythmic drugs. Implantable cardioverter defibrillators reduced sudden death and total mortality in many patients, including patients with previous ventricular arrest or symptomatic sustained ventricular arrhythmias; patients with left ventricular dysfunction due to coronary artery disease who had asymptomatic nonsustained ventricular tachycardia and sustained tachycardia that could be induced electrophysiologically; and some patients with severe left ventricular dysfunction (ejection fraction 0.3) after myocardial infarction. The Editors Research Register, the Glaxo Wellcome Clinical Trials Register, the LILACS (Latin American and Caribbean Health Science Literature) Database, OCLC (Online Computer Library Center) ProceedingsFirst, and the National Health Service Economic Evaluation Database. All databases were last accessed on 24 September In addition, bibliographies of relevant papers were hand searched and experts, device manufacturers, and primary authors were contacted for information on additional trials. Relevant conference proceedings were also searched. The search was not limited by language. We used the following textwords and Medical Subject Headings: ICD, AICD, implantable defibrillators (exp), heart arrest (exp), sudden cardiac death (exp), sudden death (exp), SCD, cardiac arrest, coronary disease (exp), heart disease (exp), systolic dysfunction, ventricular dysfunction (exp), heart failure (exp), ventric* arrhythmia, ventric* rhythm, ventric* fibrillation, ventric* tachycardia, arrhythmia (exp), anti-arrhythmia agents (exp), anti-arrhythmia drug*, anti-arrhythmia therap*, and antiarrhythmi*. Study Selection Two of the study investigators independently reviewed the titles and abstracts of all citations to identify any randomized trials evaluating the efficacy of ICDs versus placebo or ICDs versus antiarrhythmic therapy. Both reviewers used standardized data forms to review the full text of potentially relevant articles. A funnel plot was used to evaluate publication bias. We included any randomized, controlled trials involving patients at risk for sudden cardiac death or ventricular arrhythmia (sustained ventricular tachycardia or ventricular fibrillation) who had evidence of heart failure or CAD (primary prevention), as well as studies in survivors of sudden cardiac death or unstable ventricular rhythm (secondary prevention). The trial outcomes had to include sudden cardiac death or all-cause mortality. Trials in patients with inherited arrhythmic disorders were excluded. We also excluded trials that did not report any of the outcomes of interest or had crossover rates of greater than 50% between study groups. Validity Assessment and Data Abstraction Intention-to-treat analyses were performed, and the outcome definitions used by the original researchers were accepted. All discrepancies in trial eligibility or data collection were resolved by consensus. Outcome Measures We extracted data on all-cause mortality, sudden cardiac death, total cardiac mortality, and total noncardiac mortality. A priori, we decided to examine the effects of ICD therapy in primary versus secondary prevention. Because we anticipated that the primary prevention trials would encompass a broad spectrum of patients, we subdivided them into those enrolling high-risk patients and those enrolling moderate-risk patients. We defined highrisk patients as those with an expected rate of sudden cardiac death of at least 5% per year (that is, patients with ischemic cardiomyopathy, with or without ventricular arrhythmia) (14). Statistical Analysis We used Metaview 4.1 software (Update Software, Oxford, United Kingdom) to calculate summary relative risks (since the outcomes were relatively common) and used the Cochran Q-test to assess for heterogeneity in each outcome of interest. We combined studies using the Der- Simonian and Laird random-effects model as well as the Mantel Haenszel Peto fixed-effects model; when the results from both models were identical and there was no Figure 1. Selection of trials included in the meta-analysis. RCT randomized, controlled trial March 2003 Annals of Internal Medicine Volume 138 Number 6
3 Defibrillators and Sudden Cardiac Death Article Table 1. Characteristics of Included Studies* Study (Reference) Patients Control Therapy Crossover Rate Mean Age ±SD History of Resuscitated Arrest Coronary Artery Disease Men Mean Ejection Fraction ±SD Mean Followup Secondary prevention AVID (19) CASH (23) CIDS (22) Primary prevention MADIT (24) CABG Patch (20) MUSTT (21) MADIT II (13) CAT (12) 1016 patients resuscitated after near-fatal VF; sustained VT with syncope; sustained VT with EF 0.4 and symptoms 288 patients resuscitated after cardiac arrest secondary to documented ventricular arrhythmia 659 patients resuscitated after outof-hospital cardiac arrest; documented VF; sustained VT with syncope; sustained VT with EF 0.35 and symptoms; syncope and VT 196 patients with MI 3 weeks before entry; EF 0.36; NYHA class I, II, or III; asymptomatic nonsustained VT 3 to 30 beats; inducible VT on EPS not suppressed by IV procainamide; 25 to 80 years of age 900 patients with EF 0.36 and abnormalities on signal-averaged ECG; randomly assigned in OR after CABG; 80 years of age 704 patients with EF 0.40 and coronary artery disease; NYHA class I, II, or III; nonsustained VT 3 beats; inducible VT on EPS 1232 patients with MI 1 month before entry; EF 0.3; NYHA class I, II, or III; 21 years of age 104 patients with EF 0.3; NYHA class II or III; dilated cardiomyopathy 9 months; CAD excluded by angiography; excluded if history of symptomatic bradycardia, VT, or VF; all underwent EPS; 18 to 70 years of age % y 4OOOOO % OOOOO3 mo Amiodarone, sotalol Amiodarone, metoprolol, propafenone Amiodarone Antiarrhythmic drugs Usual care No antiarrhythmic therapy Usual care Usual care * AVID Antiarrhythmic versus Implantable Defibrillator; CABG coronary artery bypass grafting; CABG Patch Coronary Artery Bypass Graft Patch Trial; CAD coronary artery disease; CASH Cardiac Arrest Study Hamburg; CAT Cardiomyopathy Trial; CIDS Canadian Implantable Defibrillator Study; ECG electrocardiogram; EF ejection fraction; EPS electrophysiologic study; IV intravenous; MADIT Multicenter Automatic Defibrillator Implantation Trial; MADIT II Multicenter Automatic Defibrillator Implantation Trial II; MI myocardial infarction; MUSTT Multicenter Unsustained Tachycardia Trial; NYHA New York Heart Association; OR operating room; VF ventricular fibrillation; VT ventricular tachycardia. Only the 161 patients randomly assigned to an implantable cardioverter defibrillator and the 353 patients randomly assigned to no antiarrhythmic therapy are included in subsequent analyses; patients randomly assigned to electrophysiologically guided therapy were excluded. Median. statistical heterogeneity, we reported only the fixed effects (15). We also conducted sensitivity analyses to examine the effect of year of publication, study quality, and allocation concealment on the results (16, 17). Role of the Funding Sources The funding sources had no role in the collection, analysis, or interpretation of the data or in the decision to submit the paper for publication. RESULTS Of the 385 potentially relevant articles identified in our search, 9 were parallel-group randomized trials. We excluded 1 trial because patients in both study groups received ICD therapy (18). We then analyzed the data from the 8 trials that fulfilled our inclusion criteria (12, 13, 19 24) (Figure 1). There was no disagreement about any of the articles selected for final inclusion in the meta-analysis. Funnel-plot analyses did not suggest any marked publication bias. In the 8 trials we examined, 4909 patients were randomly assigned to study groups. Three of the 8 trials were trials of secondary prevention, and the remaining 5 (3 involving high-risk patients and 2 involving moderate-risk patients) were classified as trials of primary prevention (Table 1). All but 1 study (12) enrolled patients with ischemic heart disease. All trials reported all-cause mortal March 2003 Annals of Internal Medicine Volume 138 Number 6 447
4 Article Defibrillators and Sudden Cardiac Death Table 2. Therapies according to Treatment Assignment in the Trials* Study (Reference) Study Group ICD Aspirin ACE Inhibitor Digoxin Nonsotalol -Blocker Sotalol Amiodarone Class I Antiarrhythmic Agent 4OOOOOOOOOOOOOOOOOOOOOOOOOO n (%) OOOOOOOOOOOOOOOOOOOOOOOOOO3 AVID (19) ICD 497 (98) 308 (61) 349 (69) 237 (47) 214 (42) 10 (1) 9 (2) 21 (4) Control 51 (10) 301 (59) 347 (68) 207 (41) 84 (17) 14 (3) 488 (96) 6 (1) CASH (23) ICD 99 (100) 57 (58) 45 (45) 26 (26) 0 (0) 0 (0) 0 (0) 0 (0) Control 11 (6) 81 (43) 79 (42) 38 (20) 96 (51) 0 (0) 91 (48) 0 (0) CIDS (22) ICD 310 (95) NA NA 97 (30) 110 (34) 65 (20) 0 (0) 18 (6) Control 53 (16) NA NA 75 (23) 71 (21) 5 (2) 0 (0) 8 (2) MADIT (24) ICD 90 (95) NA 57 (60) 55 (58) 25 (26) 1 (1) 2 (2) 11 (12) Control 11 (11) NA 56 (55) 38 (38) 8 (8) 7 (7) 75 (74) 10 (10) CABG Patch (20) ICD 434 (97) 370 (83) 245 (55) 308 (69) 80 (18) 5 (1) 18 (4) 76 (17) Control 18 (4) 386 (85) 245 (54) 295 (65) 109 (24) 5 (1) 14 (3) 295 (65) MUSTT (21) ICD 161 (100) 103 (64) 116 (72) 84 (52) 47 (29) NA NA NA Control 11 (3) 222 (63) 272 (77) 187 (53) 180 (51) NA NA NA MADIT II (13) ICD 710 (96) NA 505 (68) 534 (72) 519 (70) NA 96 (13) 22 (3) Control 22 (4) NA 353 (72) 279 (57) 343 (70) NA 49 (10) 10 (2) CAT (12) ICD 46 (92) NA 47 (94) 43 (86) 2 (4) NA NA NA Control 3 (6) NA 53 (98) 41 (76) 2 (4) NA NA NA * ACE angiotensin-converting enzyme inhibitor; AVID Antiarrhythmic versus Implantable Defibrillator; CABG Patch Coronary Artery Bypass Graft Patch Trial; CASH Cardiac Arrest Study Hamburg; CAT Cardiomyopathy Trial; CIDS Canadian Implantable Defibrillator Study; ICD implantable cardioverter defibrillator; MADIT Multicenter Automatic Defibrillator Implantation Trial; MADIT II Multicenter Automatic Defibrillator Implantation Trial II; MUSTT Multicenter Unsustained Tachycardia Trial; NA not available. Received a transthoracic or epicardial lead ICD (AVID, 7%; CASH, 56%; CIDS, 10%; CABG Patch, 100%). ity, and all but 1 (21) used all-cause mortality as the primary outcome. The control groups and crossover rates are described in Table 1, and concomitant medication use is described in Table 2. The included trials were randomized and controlled. Because of the nature of the intervention, none of the trials were blinded. Randomization and allocation concealment were adequate in all trials. All-cause mortality and sudden cardiac death were reported in all trials, but other end points were not consistently reported. For several trials, we needed to review secondary publications or contact the authors to determine causes of death. The summary relative risk (RR) for sudden cardiac death was 0.43 (95% CI, 0.35 to 0.53) for all 8 trials. This confirms that ICDs are highly efficacious in preventing sudden cardiac death, both as primary prevention (RR, 0.37 [CI, 0.27 to 0.50]) and secondary prevention (RR, 0.50 [CI, 0.38 to 0.66]) (Figure 2). No appreciable heterogeneity was seen among trials, although no sudden cardiac deaths occurred in either study group in 1 trial (12) because the investigators had recruited lower-risk patients. There was no appreciable difference between types of ICD (transthoracic vs. transvenous) in the summary effect estimates for prevention of sudden cardiac death (19, 20). Four trials reported a statistically significant survival benefit in ICD-treated patients (Figure 3). The summary relative risk of 0.74 (CI, 0.67 to 0.82) for all-cause mortality in all 8 trials demonstrates a beneficial effect of ICD therapy. Effect estimates were similar in trials of primary and secondary prevention (RR, 0.72 [CI, 0.63 to 0.84] vs [CI, 0.65 to 0.89]) (Figure 3). Random-effects models yielded similar summary relative risks for overall mortality, all-cause mortality in primary prevention, and allcause mortality in secondary prevention (0.72 [CI, 0.58 to 0.90], 0.69 [CI, 0.46 to 1.03], and 0.77 [CI, 0.65 to 0.91], respectively). Substantial heterogeneity in total mortality was observed between primary prevention trials enrolling highrisk patients and those enrolling moderate-risk patients (P 0.001). Indeed, the latter trials failed to demonstrate any survival benefit with ICD therapy. This is not surprising, however, when the differences between patients enrolled in the 3 high-risk trials and the 2 moderate-risk trials are considered. In the 3 trials demonstrating a substantial survival benefit with ICDs, virtually all of the patients had known CAD and left ventricular dysfunction (Table 2); in 2 of these 3 trials, the patients also had inducible ventricular arrhythmias on electrophysiologic testing (21, 24). However, while both of the moderate-risk trials enrolled patients with left ventricular systolic dysfunction, 1 included only patients with nonischemic dilated cardiomyopathy but no inducible ventricular arrhythmia and the other enrolled patients after successful coronary artery surgery; in the latter group, the issue of myocardial ischemia was presumably resolved (20). Five trials (12, 13, 20, 22, 24) reported total cardiac mortality, with a summary point estimate of 0.81 (CI, March 2003 Annals of Internal Medicine Volume 138 Number 6
5 Defibrillators and Sudden Cardiac Death Article to 0.96) for relative risk. Noncardiac mortality did not differ between patients receiving ICDs and those receiving medical therapy alone in the 3 trials that reported this outcome (RR, 0.91 [CI, 0.60 to 1.38]) (13, 22, 24). Perioperative infection rates after ICD implantation ranged from 0.7% to 12.3% in these 8 trials, and rates of lead fracture or device malfunction ranged from 1.8% to 14%. Rates of serious bleeding ranged from 1% to 6%, and pneumothorax occurred in less than 1% of patients. Not unexpectedly, the complication rates were higher for transthoracic ICD. The more recent trials, which used newer ICD models, reported lower complication rates. The risk difference for total mortality was 0.08 (CI, 0.02 to 0.13) for all included trials, yielding a number needed to treat for benefit of 13 (CI, 8 to 50). However, this summary estimate is inadequate because its calculation varies depending on baseline risk. For example, for primary prevention, 18 patients with severe ischemic cardiomyopathy (left ventricular ejection fraction 0.3) would need to receive ICDs to prevent one death over the next 2 years (13). However, if ICDs were implanted only in patients with similar left ventricular dysfunction and inducible ventricular arrhythmias, the number needed to treat for benefit would be 4 (21, 24). DISCUSSION Implantable cardioverter defibrillators reduce the relative risk for sudden cardiac death by approximately 50%, regardless of baseline risk. However, the effect of ICD therapy on all-cause mortality varies according to baseline risk. We would expect that the impact of any intervention on a combined end point (such as total mortality) would vary if the intervention affects only one component of that end point (such as arrhythmic death). The effect of an intervention on a combined end point will be greater in highrisk persons (in whom a greater proportion of all deaths will be due to arrhythmia) and less dramatic in moderaterisk persons (in whom other causes of death will predominate) (25). As expected, while ICDs reduced all-cause mortality by approximately one third in survivors of cardiac arrest and in high-risk patients who had not yet had an arrest (for example, patients with CAD and severe left ventricular systolic dysfunction), the trials we examined did not show a significant impact on total mortality rates in patients at lower risk for sudden cardiac death (for example, patients with left ventricular systolic dysfunction but no CAD or inducible ventricular arrhythmias). Since it has been proven that ICDs are efficacious in reducing sudden cardiac deaths, the challenge is to accurately stratify patients by baseline risk to identify those most likely to benefit from ICD therapy. Our data support the policy of considering ICD therapy for secondary prevention (for example, in survivors of cardiac arrest) or for primary prevention in high-risk patients (26). However, additional research is required before we can more accurately estimate the risk for sudden cardiac death in particular patients. Figure 2. Sudden cardiac death for included trials. Relative risk (RR) is shown with box size proportional to sample size; lines indicate 95% CIs. For each stratum, the diamond represents the pooled analysis. AVID Antiarrhythmic versus Implantable Defibrillator; CABG Patch Coronary Artery Bypass Graft Patch Trial; CASH Cardiac Arrest Study Hamburg; CAT Cardiomyopathy Trial; CIDS Canadian Implantable Defibrillator Study; ICD implantable cardioverter defibrillator; MADIT Multicenter Automatic Defibrillator Implantation Trial; MADIT II Multicenter Automatic Defibrillator Implantation Trial II; MUSTT Multicenter Unsustained Tachycardia Trial March 2003 Annals of Internal Medicine Volume 138 Number 6 449
6 Article Defibrillators and Sudden Cardiac Death Figure 3. All-cause mortality for included trials. Relative risk (RR) is shown with box size proportional to sample size; lines indicate 95% CIs. For each stratum, the diamond represents the pooled analysis. AVID Antiarrhythmic versus Implantable Defibrillator; CABG Patch Coronary Artery Bypass Graft Patch Trial; CASH Cardiac Arrest Study Hamburg; CAT Cardiomyopathy Trial; CIDS Canadian Implantable Defibrillator Study; ICD implantable cardioverter defibrillator; MADIT Multicenter Automatic Defibrillator Implantation Trial; MADIT II Multicenter Automatic Defibrillator Implantation Trial II; MUSTT Multicenter Unsustained Tachycardia Trial. A collaborative individual-patient meta-analysis of the three available trials of secondary prevention established that ICDs were most beneficial in patients who were resuscitated after cardiac arrest and had ejection fractions less than or equal to 0.35 (10). A preliminary subanalysis of the data from the Multicenter Automatic Defibrillator Implantation Trial (MADIT) II found that ICDs had the greatest benefit in patients with a QRS duration greater than 0.12 seconds (27). The Amiodarone versus Implantable Defibrillator in Patients with Nonischemic Cardiomyopathy and Asymptomatic Nonsustained Ventricular Tachycardia (AMIOVIRT) Trial, a trial of primary prevention, involved 103 patients with nonischemic cardiomyopathy, ejection fraction less than 0.35, and nonsustained ventricular tachycardia. Two sudden cardiac deaths occurred in the amiodarone group, and one occurred in the ICD group. However, preliminary results from this trial did not reveal any significant difference between therapy with ICD or with amiodarone (28). These results are similar to the negative results of the Cardiomyopathy Trial (12) and confirm our findings that the benefits of ICDs on total mortality are sensitive to baseline risk for sudden cardiac death. Appendix Table. Included Trials and Their Completion Dates Acronym Trial Name Completion Date AVID Antiarrhythmic versus Implantable Defibrillator May 1997 CABG Patch Coronary Artery Bypass Graft Patch Trial April 1997 CASH Cardiac Arrest Study Hamburg March 1998 CAT Cardiomyopathy Trial June 1997 CIDS Canadian Implantable Defibrillator Study January 1997 MADIT Multicenter Automatic Defibrillator Implantation Trial March 1996 MADIT II Multicenter Automatic Defibrillator Implantation Trial II November 2001 MUSTT Multicenter Unsustained Tachycardia Trial October 1998 AMIOVIRT Amiodarone versus Implantable Defibrillator in Patients with Nonischemic November 2000* Cardiomyopathy and Asymptomatic Nonsustained Ventricular Tachycardia BEST-ICD -Blocker Strategy plus Implantable Cardioverter Defibrillator Trial 2003 DEFINITE Defibrillators in Non-ischemic Cardiomyopathy Treatment Evaluation December 2002 DINAMIT Defibrillators in Acute Myocardial Infarction Trial September 2003 MAVERIC Midlands Trial of Empirical Amiodarone versus Electrophysiology-guided January 1999* Interventions and Implantable Cardioverter-Defibrillators SCD-HeFT Sudden Cardiac Death in Heart Failure Trial October 2003 * Principal investigators contacted; manuscripts not yet in press as of 23 September March 2003 Annals of Internal Medicine Volume 138 Number 6
7 Defibrillators and Sudden Cardiac Death Article The Sudden Cardiac Death in Heart Failure Trial (SCD- HeFT), in which 2500 patients with ischemic or nonischemic cardiomyopathy and an ejection fraction less than 0.35 have been randomly assigned to amiodarone or ICD and are being followed for 2.5 years, will further refine the evidence base for primary prevention. Results are expected in As a first step, a meta-analysis using individual-patient data and incorporating the results from the 8 trials examined in our study and 6 ongoing trials with mortality end points (Appendix Table) would be invaluable in refining the definition of risk and the potential impact of ICDs in particular patient subgroups. Such a meta-analysis would also permit exploration of potential interactions between ICDs and cardiac medications, such as -blockers. Other issues that remain to be addressed by ongoing studies include the cost-effectiveness of ICD therapy and its impact on quality of life. The latter may be important in determining whether an ICD should be used because some patients may have poorer quality of life after defibrillator implantation, particularly if they receive frequent shocks. Much work is needed to clearly define which patients are at risk for worsened quality of life (29 31). A recent analysis suggested that the incremental cost-effectiveness ratio for ICD placement compared with drug therapy was $ per year of life saved in patients resuscitated after cardiac arrest (32, 33). As expected, given the variability in baseline risks among patient subgroups, incremental cost-effectiveness ratios are estimated to range from $ to $ per year of life saved (34 39). The wide variability in cost-effectiveness ratios again emphasizes the importance of accurate risk stratification tools to assist in determining who should receive ICD therapy. Our conclusions are limited by the paucity of trials in this area, particularly for some groups of patients (such as those with nonischemic cardiomyopathy). However, we used the rigorous methods of the Cochrane Collaboration to maximize the validity of our results. Given the nature of the trial reports we examined, we were unable to examine the relationship between specific baseline characteristics and the efficacy of ICDs; such analysis can be performed only in a meta-analysis using individual-patient data or a very large trial. Finally, in any systematic review, there is always concern about the potential for publication bias. However, we conducted an exhaustive search, including contact with primary study authors, device manufacturers, and experts in the field, to ensure that we had identified all relevant randomized trials, including trials with negative results. Implantable cardioverter defibrillators are clearly more beneficial than drug therapy for secondary prevention of sudden cardiac death and for primary prevention in certain high-risk groups. However, further research is needed to develop accurate risk stratification tools, to determine the economic impact of ICD therapy in different subgroups of patients, and to evaluate quality-of-life issues. From the University of Alberta, Edmonton, Alberta, Canada. Acknowledgments: The authors thank Dr. Terry Klassen, Dr. Brian Rowe, and Ms. Ellen Crumley for their assistance. Grant Support: By a CIHR Strategic Training Fellowship in TORCH (Tomorrow s Research Cardiovascular Health Professionals) (Dr. Ezekowitz) and by the Alberta Heritage Foundation for Medical Research (Dr. McAlister). Potential Financial Conflicts of Interest: None disclosed. Requests for Single Reprints: Finlay A. McAlister, MD, MSc, FRCPC, 2E3.24 Walter Mackenzie Centre, th Street, Edmonton, Alberta T6G 2B7, Canada; , finlay.mcalister@ualberta.ca. Current author addresses and author contributions are available at References 1. American Heart Association Heart and Stroke Statistical Update. Dallas, TX: American Heart Assoc; Zipes DP, Wellens HJ. Sudden cardiac death. Circulation. 1998;98: [PMID: ] 3. Kadish A. Primary prevention of sudden death using ICD therapy: incremental steps [Editorial]. J Am Coll Cardiol. 2002;39: [PMID: ] 4. Bigger JT. Expanding indications for implantable cardiac defibrillators [Editorial]. N Engl J Med. 2002;346: [PMID: ] 5. Zipes DP. Implantable cardioverter-defibrillator: a Volkswagen or a Rolls Royce: how much will we pay to save a life? [Editorial] Circulation. 2001;103: [PMID: ] 6. Nisam S, Farré J.Is prophylaxis the best use of the ICD? Eur Heart J. 2002;23: [PMID: ] 7. Myerburg RJ, Kessler KM, Castellanos A. Sudden cardiac death. Structure, function, and time-dependence of risk. Circulation. 1992;85:I2-10. [PMID: ] 8. Domanski MJ, Zipes DP, Schron E. Treatment of sudden cardiac death. Current understandings from randomized trials and future research directions. Circulation. 1997;95: [PMID: ] 9. Bigger JT Jr, Fleiss JL, Kleiger R, Miller JP, Rolnitzky LM. The relationships among ventricular arrhythmias, left ventricular dysfunction, and mortality in the 2 years after myocardial infarction. Circulation. 1984;69: [PMID: ] 10. Connolly SJ, Hallstrom AP, Cappato R, Schron EB, Kuck KH, Zipes DP, et al. Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials. AVID, CASH and CIDS studies. Antiarrhythmics vs Implantable Defibrillator study. Cardiac Arrest Study Hamburg. Canadian Implantable Defibrillator Study. Eur Heart J. 2000;21: [PMID: ] 11. Parkes J, Bryant J, Milne R. Implantable cardioverter-defibrillators in arrhythmias: a rapid and systematic review of effectiveness. Heart. 2002;87: [PMID: ] 12. Bänsch D, Antz M, Boczor S, Volkmer M, Tebbenjohanns J, Seidl K, et al. Primary prevention of sudden cardiac death in idiopathic dilated cardiomyopathy: the Cardiomyopathy Trial (CAT). Circulation. 2002;105: [PMID: ] 13. Moss AJ, Zareba W, Hall WJ, Klein H, Wilber DJ, Cannom DS, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med. 2002;346: [PMID: ] 14. Huikuri HV, Castellanos A, Myerburg RJ. Sudden death due to cardiac arrhythmias. N Engl J Med. 2001;345: [PMID: ] 15. Deeks J, Altman D, Bradburn M. Statistical methods for examining heterogeneity and combining results from several studies in meta-analysis. In: Egger M, Smith G, Altman D, eds. Systematic Reviews in Health Care: Meta-Analysis in 18 March 2003 Annals of Internal Medicine Volume 138 Number 6 451
8 Article Defibrillators and Sudden Cardiac Death Context. 2nd ed. London: BMJ Publishing Group; 2001: Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17:1-12. [PMID: ] 17. Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA. 1995;273: [PMID: ] 18. Wever EF, Hauer RN, van Capelle FL, Tijssen JG, Crijns HJ, Algra A, et al. Randomized study of implantable defibrillator as first-choice therapy versus conventional strategy in postinfarct sudden death survivors. Circulation. 1995;91: [PMID: ] 19. A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. The Antiarrhythmics versus Implantable Defibrillators (AVID) Investigators. N Engl J Med. 1997; 337: [PMID: ] 20. Bigger JT Jr. Prophylactic use of implanted cardiac defibrillators in patients at high risk for ventricular arrhythmias after coronary-artery bypass graft surgery. Coronary Artery Bypass Graft (CABG) Patch Trial Investigators. N Engl J Med. 1997;337: [PMID: ] 21. Buxton AE, Lee KL, Fisher JD, Josephson ME, Prystowsky EN, Hafley G. A randomized study of the prevention of sudden death in patients with coronary artery disease. Multicenter Unsustained Tachycardia Trial Investigators. N Engl J Med. 1999;341: [PMID: ] 22. Connolly SJ, Gent M, Roberts RS, Dorian P, Roy D, Sheldon RS, et al. Canadian implantable defibrillator study (CIDS): a randomized trial of the implantable cardioverter defibrillator against amiodarone. Circulation. 2000;101: [PMID: ] 23. Kuck KH, Cappato R, Siebels J, Rüppel R. Randomized comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from cardiac arrest: the Cardiac Arrest Study Hamburg (CASH). Circulation. 2000;102: [PMID: ] 24. Moss AJ, Hall WJ, Cannom DS, Daubert JP, Higgins SL, Klein H, et al. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators. N Engl J Med. 1996;335: [PMID: ] 25. McAlister FA. Commentary: relative treatment effects are consistent across the spectrum of underlying risks...usually. Int J Epidemiol. 2002;31:76-7. [PMID: ] 26. Gregoratos G, Cheitlin MD, Conill A, Epstein AE, Fellows C, Ferguson TB Jr, et al. ACC/AHA Guidelines for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices: Executive Summary a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Pacemaker Implantation). Circulation. 1998;97: [PMID: ] 27. QRS duration could single out post-mi patients who benefit most from an ICD: MADIT II substudy. Available at Strickberger SA, Hummel JD, Bartlett TG, Frumin HI, Schuger CD, Beau SL, et al. Amiodarone versus implantable defibrillator randomized trial in patients with nonischemic dilated cardiomyopathy and asymptomatic nonsustained ventricular tachycardia: AMIOVIRT. The AMIOVIRT Investigators. J Am Coll Cardiol. 2003; [In press]. 29. Schron EB, Exner DV, Yao Q, Jenkins LS, Steinberg JS, Cook JR, et al. Quality of life in the antiarrhythmics versus implantable defibrillators trial: impact of therapy and influence of adverse symptoms and defibrillator shocks. Circulation. 2002;105: [PMID: ] 30. Irvine J, Dorian P, Baker B, O Brien BJ, Roberts R, Gent M, et al. Quality of life in the Canadian Implantable Defibrillator Study (CIDS). Am Heart J. 2002;144: [PMID: ] 31. Exner DV. Quality of life in patients with life-threatening arrhythmias: does choice of therapy make a difference? [Editorial] Am Heart J. 2002;144: [PMID: ] 32. Larsen G, Hallstrom A, McAnulty J, Pinski S, Olarte A, Sullivan S, et al. Cost-effectiveness of the implantable cardioverter-defibrillator versus antiarrhythmic drugs in survivors of serious ventricular tachyarrhythmias: results of the Antiarrhythmics Versus Implantable Defibrillators (AVID) economic analysis substudy. Circulation. 2002;105: [PMID: ] 33. Larsen GC, Manolis AS, Sonnenberg FA, Beshansky JR, Estes NA, Pauker SG. Cost-effectiveness of the implantable cardioverter-defibrillator: effect of improved battery life and comparison with amiodarone therapy. J Am Coll Cardiol. 1992;19: [PMID: ] 34. Sheldon R, O Brien BJ, Blackhouse G, Goeree R, Mitchell B, Klein G, et al. Effect of clinical risk stratification on cost-effectiveness of the implantable cardioverter-defibrillator: the Canadian implantable defibrillator study. Circulation. 2001;104: [PMID: ] 35. Sanders GD, Hlatky MA, Every NR, McDonald KM, Heidenreich PA, Parsons LS, et al. Potential cost-effectiveness of prophylactic use of the implantable cardioverter defibrillator or amiodarone after myocardial infarction. Ann Intern Med. 2001;135: [PMID: ] 36. Owens DK, Sanders GD, Harris RA, McDonald KM, Heidenreich PA, Dembitzer AD, et al. Cost-effectiveness of implantable cardioverter defibrillators relative to amiodarone for prevention of sudden cardiac death. Ann Intern Med. 1997;126:1-12. [PMID: ] 37. O Brien BJ, Connolly SJ, Goeree R, Blackhouse G, Willan A, Yee R, et al. Cost-effectiveness of the implantable cardioverter-defibrillator: results from the Canadian Implantable Defibrillator Study (CIDS). Circulation. 2001;103: [PMID: ] 38. Kuppermann M, Luce BR, McGovern B, Podrid PJ, Bigger JT Jr, Ruskin JN. An analysis of the cost effectiveness of the implantable defibrillator. Circulation. 1990;81: [PMID: ] 39. Mushlin AI, Hall WJ, Zwanziger J, Gajary E, Andrews M, Marron R, et al. The cost-effectiveness of automatic implantable cardiac defibrillators: results from MADIT. Multicenter Automatic Defibrillator Implantation Trial. Circulation. 1998;97: [PMID: ] March 2003 Annals of Internal Medicine Volume 138 Number 6
9 Current Author Addresses: Drs. Ezekowitz and Armstrong: 2-51 Medical Sciences Building, University of Alberta, Edmonton, Alberta T6G 2H7, Canada. Dr. McAlister: 2E3.24 Walter Mackenzie Centre, th Street, Edmonton, Alberta T6G 2B7, Canada. Author Contributions: Conception and design: J.A. Ezekowitz, F. McAlister. Analysis and interpretation of the data: J.A. Ezekowitz, P.W. Armstrong, F. McAlister. Drafting of the article: J.A. Ezekowitz, P.W. Armstrong, F. McAlister. Critical revision of the article for important intellectual content: J.A. Ezekowitz, P.W. Armstrong, F. McAlister. Final approval of the article: J.A. Ezekowitz, P.W. Armstrong, F. McAlister. Provision of study materials or patients: J.A. Ezekowitz. Statistical expertise: J.A. Ezekowitz, F. McAlister. Obtaining of funding: P.W. Armstrong. Administrative, technical, or logistic support: J.A. Ezekowitz, P.W. Armstrong. Collection and assembly of data: J.A. Ezekowitz, F. McAlister. Annals of Internal Medicine Volume Number E-453
Arrhythmias Focused Review. Who Needs An ICD?
Who Needs An ICD? Cesar Alberte, MD, Douglas P. Zipes, MD, Krannert Institute of Cardiology, Indiana University School of Medicine, Indianapolis, IN Sudden cardiac arrest is one of the most common causes
More informationImplantable Cardioverter Defibrillator Therapy in MADIT II Patients with Signs and Symptoms of Heart Failure
Implantable Cardioverter Defibrillator Therapy in MADIT II Patients with Signs and Symptoms of Heart Failure Wojciech Zareba Postinfarction patients with left ventricular dysfunction are at increased risk
More informationSecondary prevention of sudden cardiac death
Secondary prevention of sudden cardiac death Balbir Singh, MD, DM; Lakshmi N. Kottu, MBBS, Dip Card, PGPCard Department of Cardiology, Medanta Medcity Hospital, Gurgaon, India Abstract All randomised secondary
More informationWhat Every Physician Should Know:
What Every Physician Should Know: The Canadian Heart Rhythm Society estimates that, in Canada, sudden cardiac death (SCD) is responsible for about 40,000 deaths annually; more than AIDS, breast cancer
More informationMeta-analysis of the implantable cardioverter defibrillator secondary prevention trials
European Heart Journal (2000) 21, 2071 2078 doi.10.1053/euhj.2000.2476, available online at http://www.idealibrary.com on Meta-analysis of the implantable cardioverter defibrillator secondary prevention
More informationThe concept of the implantable cardioverter-defibrillator (ICD) was introduced
Review Rohit Kedia, MD Mohammad Saeed, MD, FACC Implantable Cardioverter-Defibrillators Indications and Unresolved Issues Since the implantable cardioverter-defibrillator was first used clinically in 1980,
More informationICD. Guidelines and Critical Review of Trials. Win K. Shen, MD Professor of Medicine Mayo Clinic College of Medicine Mayo Clinic Arizona Torino 2011
ICD Guidelines and Critical Review of Trials Win K. Shen, MD Professor of Medicine Mayo Clinic College of Medicine Mayo Clinic Arizona Torino 2011 Disclosure Relevant Financial Relationship(s) None Off
More informationPrimary prevention ICD recipients: the need for defibrillator back-up after an event-free first battery service-life
Chapter 3 Primary prevention ICD recipients: the need for defibrillator back-up after an event-free first battery service-life Guido H. van Welsenes, MS, Johannes B. van Rees, MD, Joep Thijssen, MD, Serge
More information20 ng/ml 200 ng/ml 1000 ng/ml chronic kidney disease CKD Brugada 5 Brugada Brugada 1
Symposium 39 45 1 1 2005 2008 108000 59000 55 1 3 0.045 1 1 90 95 5 10 60 30 Brugada 5 Brugada 80 15 Brugada 1 80 20 2 12 X 2 1 1 brain natriuretic peptide BNP 20 ng/ml 200 ng/ml 1000 ng/ml chronic kidney
More informationSudden cardiac death is a major public health problem. Article
Annals of Internal Medicine Article Clinical and Economic Implications of the Multicenter Automatic Defibrillator Implantation Trial-II Sana M. Al-Khatib, MD, MHS; Kevin J. Anstrom, PhD; Eric L. Eisenstein,
More informationHeart Failure and Implantable Cardioverter Defibrillator (ICD) Therapy: Update and Perspective on Current Primary Prevention Trials
Journal of Cardiac Failure Vol. 8 No. 3 2002 Perspectives Heart Failure and Implantable Cardioverter Defibrillator (ICD) Therapy: Update and Perspective on Current Primary Prevention Trials LESLIE A. SAXON,
More informationSudden death as co-morbidity in patients following vascular intervention
Sudden death as co-morbidity in patients following vascular intervention Impact of ICD therapy Seah Nisam Director, Medical Science, Guidant Corporation Advanced Angioplasty Meeting (BCIS) London, 16 Jan,
More informationMichel Mirowski and colleagues ABSTRACT CARDIOLOGY. ICD Update: New Evidence and Emerging Clinical Roles in Primary Prevention of Sudden Cardiac Death
ICD Update: New Evidence and Emerging Clinical Roles in Primary Prevention of Sudden Cardiac Death Ronald D. Berger, MD, PhD, FACC ABSTRACT PURPOSE: To review recent major randomized trials of implantable
More informationDo All Patients With An ICD Indication Need A BiV Pacing Device?
Do All Patients With An ICD Indication Need A BiV Pacing Device? Muhammad A. Hammouda, MD Electrophysiology Laboratory Department of Critical Care Medicine Cairo University Etiology and Pathophysiology
More informationSeveral clinical trials show that implantable cardioverterdefibrillators
Review Annals of Internal Medicine Meta-analysis: Age and Effectiveness of Prophylactic Implantable Cardioverter-Defibrillators Pasquale Santangeli, MD; Luigi Di Biase, MD; Antonio Dello Russo, MD; Michela
More informationEditorial: Sudden Death in Heart Failure: An Ounce of Prediction is Worth a Pound of Prevention
Editorial: Sudden Death in Heart Failure: An Ounce of Prediction is Worth a Pound of Prevention Sudden Cardiac Death Ragavendra R. Baliga, MD, MBA Consulting Editors James B. Young, MD Sudden cardiac death
More information417 Brazilian Journal of Cardiovascular Surgery REVIEW ARTICLE
REVIEW ARTICLE Effectiveness of Implantation of Cardioverter- Defibrillators Therapy in Patients with Non-Ischemic Heart Failure: an Updated Systematic Review and Meta-Analysis Zhenhua Xing 1, MD; Liang
More informationDefibrillation threshold testing should no longer be performed: contra
Defibrillation threshold testing should no longer be performed: contra Andreas Goette St. Vincenz-Hospital Paderborn Dept. of Cardiology and Intensive Care Medicine Germany No conflict of interest to disclose
More informationRisk Stratification of Sudden Cardiac Death
Risk Stratification of Sudden Cardiac Death Michael R Gold, MD, PhD Medical University of South Carolina Charleston, SC USA Disclosures: None Sudden Cardiac Death A Major Public Health Problem > 1/2 of
More informationEditorial TREATMENT OF SUDDEN CARDIAC DEATH SURVIVORS: DRUGS VERSUS DEVICE
Editorial TREATMENT OF SUDDEN CARDIAC DEATH SURVIVORS: DRUGS VERSUS DEVICE Patients who survive an episode of sustained ventricular trachycardia (VT) or out-of-hospital ventricular fibrillation (VF) are
More informationThe Role of ICD Therapy in Cardiac Resynchronization
The Role of ICD Therapy in Cardiac Resynchronization The Korean Society of Circulation 15 April 2005 Angel R. León, MD Carlyle Fraser Heart Center Division of Cardiology Emory University School of Medicine
More informationThe Harvard community has made this article openly available. Please share how this access benefits you. Your story matters.
Effectiveness of prophylactic implantation of cardioverterdefibrillators without cardiac resynchronization therapy in patients with ischaemic or non-ischaemic heart disease: a systematic review and meta-analysis
More informationPrimary prevention of SCD with the ICD in Nonischemic Cardiomyopathy
Primary prevention of SCD with the ICD in Nonischemic Cardiomyopathy Michael R Gold, MD, PhD Medical University of South Carolina Charleston, SC USA Disclosures: Consulting and Clinical Trials Medtronic
More informationWearable Cardioverter-Defibrillators
Wearable Cardioverter-Defibrillators Policy Number: 2.02.15 Last Review: 12/2013 Origination: 10/1988 Next Review: 12/2014 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage
More informationPublic Statement: Medical Policy Statement:
Medical Policy Title: Cardioverter- ARBenefits Approval: 09/7/2011 Defibrillators Effective Date: 01/01/2012 Document: ARB0096 Revision Date: Code(s): C1721, C1722, C1777, C1882, C1895, C1896 and C1899
More informationThe Italian Implantable Cardioverter- Defibrillator Registry. A survey of the national activity during the years
The Italian Implantable Cardioverter- Defibrillator Registry. A survey of the national activity during the years 2001-2003 Alessandro Proclemer, Marco Ghidina*, Gloria Cicuttini*, Dario Gregori*, Paolo
More informationCost-Effectiveness of Implantable Cardioverter Defibrillators
The new england journal of medicine special article Cost-Effectiveness of Implantable Cardioverter Defibrillators Gillian D. Sanders, Ph.D., Mark A. Hlatky, M.D., and Douglas K. Owens, M.D. abstract background
More informationAtrial fibrillation (AF) is a disorder seen
This Just In... An Update on Arrhythmia What do recent studies reveal about arrhythmia? In this article, the authors provide an update on atrial fibrillation and ventricular arrhythmia. Beth L. Abramson,
More informationStudy population The study population comprised patients with NIDCM and asymptomatic NSVT. The inclusion criteria were:
Amiodarone versus implantable cardioverter-defibrillator: randomized nonischemic dilated cardiomyopathy and asymptomatic nonsustained ventricular tachycardia - AMIOVIRT Strickberger S A, Hummel J D, Bartlett
More informationTHE ROLE OF ICD THERAPY FOR PRIMARY PREVENTION Leonard Ganz, M.D. Pittsburgh, PA
THE ROLE OF ICD THERAPY FOR PRIMARY PREVENTION Leonard Ganz, M.D. Pittsburgh, PA Speakers Bureau: Zoll / Lifecore, Sanofi Aventis, Cardionet Consultant: Boston Scientific, St. Jude Medical, Biotronik,
More informationICD Therapy. Disclaimers
ICD Therapy Rodney Horton, MD Texas Cardiac Arrhythmia Institute Texas Cardiovascular, PA Austin, TX Speaker s Bureau St. Jude Medical Medtronic Boston Scientific Disclaimers Clinical Advisory Panel St.
More informationPreventing Sudden Death Current & Future Role of ICD Therapy
Preventing Sudden Death Current & Future Role of ICD Therapy Derek V Exner, MD, MPH, FRCPC, FACC, FAHA, FHRS Professor, Libin Cardiovascular Institute of Alberta Canada Research Chair, Cardiovascular Clinical
More informationManagement of Syncope in Heart Failure. University of Iowa
Management of Syncope in Heart Failure Brian Olshansky University of Iowa 1 Syncope Transient loss of consciousness, with rapid, usually complete, recovery, with or without prodrome A common, non-specific,
More informationImplantation-Related Complications of Implantable Cardioverter-Defibrillators and Cardiac Resynchronization Therapy Devices
Journal of the American College of Cardiology Vol. 58, No. 10, 2011 2011 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2011.06.007
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Implantable Cardioverter Defibrillators Page 1 of 44 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: See also: Implantable Cardioverter Defibrillators Wearable Cardioverter
More informationPrevention of sudden cardiac death: With an emphasis on sudden cardiac death from ventricular arrhythmias
Prevention of sudden cardiac death: With an emphasis on sudden cardiac death from ventricular arrhythmias The Toronto ACS Summit Toronto, March 1, 2014 Andrew C.T. Ha, MD, MSc, FRCPC Cardiac Electrophysiology
More informationSudden cardiac death. (Heart Rhythm 2010;7: ) 2010 Heart Rhythm Society. All rights reserved.
Gender differences in clinical outcome and primary prevention defibrillator benefit in patients with severe left ventricular dysfunction: A systematic review and meta-analysis Pasquale Santangeli, MD,*
More informationChapter 2. Long-term follow-up of primary and secondary prevention implantable cardioverter defibrillator patients
Chapter 2 Long-term follow-up of primary and secondary prevention implantable cardioverter defibrillator patients Guido H. van Welsenes, MS, Johannes B. van Rees, MD, C. Jan Willem Borleffs, MD, PhD, Suzanne
More informationOriginal Article Risk of Death and Recurrent Ventricular Arrhythmias in Survivors of Cardiac Arrest Concurrent With Acute Myocardial Infarction
www.ipej.org 5 Original Article Risk of Death and Recurrent Ventricular Arrhythmias in Survivors of Cardiac Arrest Concurrent With Acute Myocardial Infarction Ish Singla MD*, Haitham Hreybe MD*, Samir
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Implantable cardioverter defibrillators for the treatment of arrhythmias and cardiac resynchronisation therapy for the treatment of heart failure (review
More informationMicrovolt T-Wave Alternans and the Risk of Death or Sustained Ventricular Arrhythmias in Patients With Left Ventricular Dysfunction
Journal of the American College of Cardiology Vol. 47, No. 2, 2006 2006 by the American College of Cardiology Foundation ISSN 0735-1097/06/$32.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2005.11.026
More informationThe Multicenter Unsustained Tachycardia Trial (MUSTT)
Effect of Implantable Defibrillators on Arrhythmic Events and Mortality in the Multicenter Unsustained Tachycardia Trial Kerry L. Lee, PhD; Gail Hafley, MS; John D. Fisher, MD; Michael R. Gold, MD; Eric
More informationSilvia G Priori MD PhD
The approach to the cardiac arrest survivor Silvia G Priori MD PhD Molecular Cardiology, IRCCS Fondazione Salvatore Maugeri Pavia, Italy AND Leon Charney Division of Cardiology, Cardiovascular Genetics
More informationChapter 3. Eur Heart J 2009; 30:
Recurrence of Ventricular Arrhythmias in Ischemic Secondary Prevention ICD Recipients: Long-term Followup of the Leiden Out-of- Hospital Cardiac Arrest Study (LOHCAT) C. Jan Willem Borleffs, MD 1, Lieselot
More informationJournal of the American College of Cardiology Vol. 37, No. 2, by the American College of Cardiology ISSN /01/$20.
Journal of the American College of Cardiology Vol. 37, No. 2, 2001 2001 by the American College of Cardiology ISSN 0735-1097/01/$20.00 Published by Elsevier Science Inc. PII S0735-1097(00)01133-5 Coronary
More informationSignal-Averaged Electrocardiography (SAECG)
Medical Policy Manual Medicine, Policy No. 21 Signal-Averaged Electrocardiography (SAECG) Next Review: April 2018 Last Review: April 2017 Effective: May 1, 2017 IMPORTANT REMINDER Medical Policies are
More informationIHCP bulletin INDIANA HEALTH COVERAGE PROGRAMS BT JANUARY 24, 2012
IHCP bulletin INDIANA HEALTH COVERAGE PROGRAMS BT201203 JANUARY 24, 2012 The IHCP to reimburse implantable cardioverter defibrillators separately from outpatient implantation Effective March 1, 2012, the
More informationCorporate Medical Policy
Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: signal_averaged_ecg 7/1992 10/2017 10/2018 10/2017 Description of Procedure or Service Signal-averaged electrocardiography
More informationCost-Effectiveness of the Implantable Cardioverter- Defibrillator Versus Antiarrhythmic Drugs in Survivors of Serious Ventricular Tachyarrhythmias
Cost-Effectiveness of the Implantable Cardioverter- Defibrillator Versus Antiarrhythmic Drugs in Survivors of Serious Ventricular Tachyarrhythmias Results of the Antiarrhythmics Versus Implantable Defibrillators
More informationCurrent guidelines for device-based therapy of cardiac
Long-Term Benefit of Primary Prevention With an Implantable Cardioverter-Defibrillator An Extended 8-Year Follow-Up Study of the Multicenter Automatic Defibrillator Implantation Trial II Ilan Goldenberg,
More informationJean François Leclercq Department of Rythmology Private Hospital of Parly 2 - Le Chesnay F
SECONDARY PREVENTION of Sudden Death: in which patients? Jean François Leclercq Department of Rythmology Private Hospital of Parly 2 - Le Chesnay F Why an AID is effective? Because it stoppes a VT very
More informationSudden cardiac death (SCD) is a
Management of malignant ventricular arrhythmias and cardiac arrest Richard I. Fogel, MD; Eric N. Prystowsky, MD Sudden cardiac death continues to be a major health problem in the United States, accounting
More informationhad non-continuous enrolment in Medicare Part A or Part B during the year following initial admission;
Effectiveness and cost-effectiveness of implantable cardioverter defibrillators in the treatment of ventricular arrhythmias among Medicare beneficiaries Weiss J P, Saynina O, McDonald K M, McClellan M
More informationESC Stockholm Arrhythmias & pacing
ESC Stockholm 2010 Take Home Messages for Practitioners Arrhythmias & pacing Prof. Panos E. Vardas Professor of Cardiology Heraklion University Hospital Crete, Greece Disclosures Small teaching fees from
More informationImplantable cardioverter-defibrillators (ICD) terminate
Primary Prevention of Sudden Cardiac Death in Idiopathic Dilated Cardiomyopathy The Cardiomyopathy Trial (CAT) Dietmar Bänsch, MD; Matthias Antz, MD; Sigrid Boczor; Marius Volkmer, MD; Jürgen Tebbenjohanns,
More informationWho does not need a primary preventive ICD?
Who does not need a primary preventive ICD? Hildegard Tanner, Bern Universitätsklinik für Kardiologie Disclosure of potential conflicts of interest Travel grants for educational purposes from: Biosense
More informationCover Page. The handle holds various files of this Leiden University dissertation.
Cover Page The handle http://hdl.handle.net/1887/9358 holds various files of this Leiden University dissertation. Author: Thijssen, Joep Title: Clinical aspects and socio-economic implications of implantable
More informationSynopsis of Management on Ventricular arrhythmias. M. Soni MD Interventional Cardiologist
Synopsis of Management on Ventricular arrhythmias M. Soni MD Interventional Cardiologist No financial disclosure Premature Ventricular Contraction (PVC) Ventricular Bigeminy Ventricular Trigeminy Multifocal
More informationManagement of Ventricular Arrhythmias A Trial-based Approach
Journal of the American College of Cardiology Vol. 34, No. 3, 1999 1999 by the American College of Cardiology ISSN 0735-1097/99/$20.00 Published by Elsevier Science Inc. PII S0735-1097(99)00273-9 REVIEW
More informationMedical Policy Manual. Topic: Wearable Cardioverter-Defibrillators as a Bridge to Implantable Cardioverter-Defibrillator Placement
Medical Policy Manual Topic: Wearable Cardioverter-Defibrillators as a Bridge to Implantable Cardioverter-Defibrillator Placement Date of Origin: February 5, 2003 Section: Durable Medical Equipment Last
More informationProphylactic ablation
Ventricular tachycardia in ischaemic heart disease. Update on electrical therapy 29 august 2010 Prophylactic ablation Pasquale Notarstefano Cardiovacular Department S. Donato Hospital, Arezzo (IT) Prophylactic
More informationTachycardia Devices Indications and Basic Trouble Shooting
Tachycardia Devices Indications and Basic Trouble Shooting Peter A. Brady, MD., FRCP Cardiology Review Course London, March 6 th, 2014 2011 MFMER 3134946-1 Tachycardia Devices ICD Indications Primary and
More informationOriginal Policy Date
MP 7.01.32 Implantable Cardioverter Defibrillator (ICD) Medical Policy Section Surgery Issue 12:2013 Original Policy Date 12:2013 Last Review Status/Date Reviewed with literature search/12:2013 Return
More informationLong-term follow-up of primary and secondary prevention implantable cardioverter defibrillator patients
Europace (2011) 13, 389 394 doi:10.1093/europace/euq494 CLINICAL RESEARCH Implantable Cardioverter-Defibrillators Long-term follow-up of primary and secondary prevention implantable cardioverter defibrillator
More informationCRT-P or CRT-D From North Alberta to Nairobi
CRT-P or CRT-D From North Alberta to Nairobi Dr Mzee Ngunga Aga Khan University Hospital Nairobi KCS Congress: Impact through collaboration CONTACT: Tel. +254 735 833 803 Email: kcardiacs@gmail.com Web:
More informationImplantable Cardiac Arrhythmia Devices Part II: Implantable Cardioverter Defibrillators and Implantable Loop Recorders
Clin. Cardiol. 29, 237 242 (2006) Implantable Cardiac Arrhythmia Devices Part II: Implantable Cardioverter Defibrillators and Implantable Loop Recorders FRED KUSUMOTO, M.D., AND NORA GOLDSCHLAGER, M.D.*
More informationImprovements in 25 Years of Implantable Cardioverter Defibrillator Therapy
Neth Heart J (2011) 19:24 30 DOI 10.1007/s12471-010-0047-3 REVIEW ARTICLE - E-LEARNING Improvements in 25 Years of Implantable Cardioverter Defibrillator Therapy G. H. van Welsenes & C. J. W. Borleffs
More informationComparison of clinical trials evaluating cardiac resynchronization therapy in mild to moderate heart failure
HOT TOPIC Cardiology Journal 2010, Vol. 17, No. 6, pp. 543 548 Copyright 2010 Via Medica ISSN 1897 5593 Comparison of clinical trials evaluating cardiac resynchronization therapy in mild to moderate heart
More informationMedical Policy An Independent Licensee of the Blue Cross and Blue Shield Association
Cardioverter-Defibrillators Page 1 of 32 Medical Policy An Independent Licensee of the Blue Cross and Blue Shield Association Title: Cardioverter-Defibrillators Professional Institutional Original Effective
More informationjournal of medicine The new england Sudden Death in Patients with Myocardial Infarction and Left Ventricular Dysfunction, Heart Failure, or Both
The new england journal of medicine established in 1812 june 23, 2005 vol. 352 no. 25 Sudden Death in Patients with Myocardial Infarction and Left Ventricular Dysfunction, Heart Failure, or Both Scott
More informationCover Page. The handle holds various files of this Leiden University dissertation
Cover Page The handle http://hdl.handle.net/1887/29823 holds various files of this Leiden University dissertation Author: Bie, M.K. de Title: Prevention of sudden cardiac death in patients with chronic
More informationSudden Cardiac Death
Sudden Cardiac Death management challenges of a global problem Zayd A. Eldadah, MD, PhD Co-Director, Cardiac Electrophysiology, Washington Hospital Center Director, Cardiac Electrophysiology, Georgetown
More informationAutomatic External Defibrillators
Last Review Date: April 21, 2017 Number: MG.MM.DM.10dC3v4 Medical Guideline Disclaimer Property of EmblemHealth. All rights reserved. The treating physician or primary care provider must submit to EmblemHealth
More informationShock Reduction Strategies Michael Geist E. Wolfson MC
Shock Reduction Strategies Michael Geist E. Wolfson MC Shock Therapy Thanks, I needed that! Why Do We Need To Reduce Shocks Long-term outcome after ICD and CRT implantation and influence of remote device
More informationAccepted Manuscript S (12) Reference: HRTHM To appear in: Heart Rhythm. Received date: 15 February 2012
Accepted Manuscript The Mode of Death in Implantable Cardioverter Defibrillator and Cardiac Resynchronization Therapy Defibrillator Patients: Results from Routine Clinical Practice Joep Thijssen, Johannes
More informationSudden cardiac death and implantable cardioverter defibrillators: two modern epidemics?
Europace (2012) 14, 787 794 doi:10.1093/europace/eus001 REVIEW Sudden cardiac death and implantable cardioverter defibrillators: two modern epidemics? Demosthenes G. Katritsis 1,2 * and Mark E. Josephson
More informationDevice Update Implantable Cardioverter Defibrillator (ICD) 박상원
2012 년춘계학술대회 Device Update Implantable Cardioverter Defibrillator (ICD) 박상원 Arrhythmia Center, KUMC www.korea-heartrhythm.com Korea University Medical Center Seoul, Korea The Development of ICD by a team
More informationRe: National Coverage Analysis (NCA) for Implantable Cardioverter Defibrillators (CAG R4)
December 20, 2017 Ms. Tamara Syrek-Jensen Director, Coverage & Analysis Group Centers for Medicare & Medicaid Services 7500 Security Boulevard Baltimore, MD 21244 Re: National Coverage Analysis (NCA) for
More information2017 AHA/ACC/HRS Ventricular Arrhythmias and Sudden Cardiac Death Guideline. Top Ten Messages. Eleftherios M Kallergis, MD, PhD, FESC
2017 AHA/ACC/HRS Ventricular Arrhythmias and Sudden Cardiac Death Guideline Top Ten Messages Eleftherios M Kallergis, MD, PhD, FESC Cadiology Department - Heraklion University Hospital No actual or potential
More informationIntroduction. CLINICAL RESEARCH Clinical Trial Design. Mohammad Saeed 1 *, Mehdi Razavi 1, Curtis G. Neason 2, and Simona Petrutiu 2. Aims.
Europace (2011) 13, 1648 1652 doi:10.1093/europace/eur195 CLINICAL RESEARCH Clinical Trial Design Rationale and design for programming implantable cardioverter defibrillators in patients with primary prevention
More informationAntiarrhythmic Drugs and Ablation in Patients with ICD and Shocks
Antiarrhythmic Drugs and Ablation in Patients with ICD and Shocks Alireza Ghorbani Sharif, MD Interventional Electrophysiologist Tehran Arrhythmia Clinic January 2016 Recurrent ICD shocks are associated
More informationT-Wave Alternans. Policy # Original Effective Date: 06/05/2002 Current Effective Date: 09/17/2014
Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided
More informationCardiac Devices CRT,ICD: Who is and is not a Candidate? Who Decides
Cardiac Devices CRT,ICD: Who is and is not a Candidate? Who Decides Colette Seifer MB(Hons) FRCP(UK) Associate Professor, University of Manitoba, Cardiologist, Cardiac Sciences Program, St Boniface Hospital
More informationSubcutaneous Implantable Cardioverter Defibrillator (ICD) System
Subcutaneous Implantable Cardioverter Defibrillator (ICD) System Policy Number: Original Effective Date: MM.06.025 07/01/2015 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 3/24/201701/01/2019
More informationVentricular Tachycardia Ablation. Saverio Iacopino, MD, FACC, FESC
Ventricular Tachycardia Ablation Saverio Iacopino, MD, FACC, FESC ü Ventricular arrhythmias, both symptomatic and asymptomatic, are common, but syncope and SCD are infrequent initial manifestations of
More informationQRS Duration Does Not Predict Occurrence of Ventricular Tachyarrhythmias in Patients With Implanted Cardioverter-Defibrillators
Journal of the American College of Cardiology Vol. 46, No. 2, 2005 2005 by the American College of Cardiology Foundation ISSN 0735-1097/05/$30.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2005.03.060
More information1. SUDDEN CARDIAC DEATH IN HEART FAILURE
6 Implantable Cardioverter-Defibrillators Rachel Lampert, MD and Zachary Goldberger, MD CONTENTS SUDDEN CARDIAC DEATH IN HEART FAILURE INDICATIONS FOR ICD IMPLANTATION IN PATIENTS WITH HF ICD FUNCTION
More informationRisk Stratification and Benefit of ICD-Therapy in Congestive Heart Failure Patients
120 April 2001 Risk Stratification and Benefit of ICD-Therapy in Congestive Heart Failure Patients P. SCHIRDEWAHN, G. HINDRICKS, H. KOTTKAMP Department of Cardiology, University of Leipzig Heart Center,
More informationDevice Based Therapy for the Failing Heart: ICD and Cardiac Resynchronization Rx
Device Based Therapy for the Failing Heart: ICD and Cardiac Resynchronization Rx Charles Gottlieb, MD Director of Electrophysiology Abington Memorial Hospital Heart Failure Mortality Mechanism of death
More informationSudden Cardiac Death What an electrophysiologist thinks a cardiologist should know
Sudden Cardiac Death What an electrophysiologist thinks a cardiologist should know Steven J. Kalbfleisch, M.D. Medical Director Electrophysiology Laboratory Ross Heart Hospital Wexner Medical Center Sudden
More informationPause-induced Ventricular Tachycardia: Clinical Characteristics
Pause-induced Ventricular Tachycardia: Clinical Characteristics Margaret Bond A. Study Purpose and Rationale Until three decades ago, ventricular arrhythmias were thought to be rare in occurrence and their
More informationIMPLANTABLE DEVICE THERAPY FOR HEART FAILURE
IMPLANTABLE DEVICE THERAPY FOR HEART FAILURE Nora Goldschlager, M.D. MACP, FACC, FAHA, FHRS Cardiology San Francisco General Hospital UCSF Disclosures: None LEADING CAUSES OF DEATH IN US Sudden cardiac
More informationThe Therapeutic Role of the Implantable Cardioverter Defibrillator in Arrhythmogenic Right Ventricular Dysplasia
The Therapeutic Role of the Implantable Cardioverter Defibrillator in Arrhythmogenic Right Ventricular Dysplasia By Sandeep Joshi, MD and Jonathan S. Steinberg, MD Arrhythmia Service, Division of Cardiology
More informationTremendous strides have been made in recent years in the treatment and prevention of
Treatment and Prevention of Sudden Cardiac Death Effect of Recent Clinical Trials Jeffrey J. Goldberger, MD REVIEW ARTICLE Tremendous strides have been made in recent years in the treatment and prevention
More informationMEDICAL POLICY SUBJECT: IMPLANTABLE CARDIOVERTER DEFIBRILLATOR
MEDICAL POLICY SUBJECT: IMPLANTABLE CARDIOVERTER PAGE: 1 OF: 12 If a product excludes coverage for a service, it is not covered, and medical policy criteria do not apply. If a commercial product, including
More informationThe implantable cardioverter defibrillator (ICD) is a
Annals of Internal Medicine Review Effectiveness of Implantable Cardioverter Defibrillators for Primary Prevention of Sudden Cardiac Death in Subgroups A Systematic Review Amy Earley, BS; Rebecca Persson,
More informationThe implantable cardioverter defibrillator is not enough: Ventricular Tachycardia Catheter Ablation in Patients with Structural Heart Disease
The implantable cardioverter defibrillator is not enough: Ventricular Tachycardia Catheter Ablation in Patients with Structural Heart Disease Paolo Della Bella, MD Arrhythmia Department and Clinical Electrophysiology
More informationLong-Term Prognosis of Patients with an Implantable Cardioverter-Defibrillator in Korea
Original Article Yonsei Med J 2017 May;58(3):514-520 pissn: 0513-5796 eissn: 1976-2437 Long-Term Prognosis of Patients with an Implantable Cardioverter-Defibrillator in Korea Jae-Sun Uhm, Tae-Hoon Kim,
More informationImplantable Cardioverter Defibrillator. Description
Subject: Implantable Cardioverter Defibrillator Page: 1 of 41 Last Review Status/Date: December 2015 Implantable Cardioverter Defibrillator Description The automatic implantable cardioverter defibrillator
More informationWearable Cardioverter Defibrillators
Protocol Wearable Cardioverter Defibrillators Medical Benefit Effective Date: 08/01/17 Next Review Date: 05/19 Preauthorization Yes Review Dates: 05/07, 05/08, 05/09, 03/10, 01/11, 01/12, 01/13, 01/14,
More information